|Other Names||Tumor necrosis factor ligand superfamily member 10, Apo-2 ligand, Apo-2L, TNF-related apoptosis-inducing ligand, Protein TRAIL, CD253, TNFSF10, APO2L, TRAIL|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG. Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis.|
|Cellular Location||Membrane; Single-pass type II membrane protein|
|Tissue Location||Widespread; most predominant in spleen, lung and prostate|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The protein encoded by this gene is a cytokine thatbelongs to the tumor necrosis factor (TNF) ligand family. Thisprotein preferentially induces apoptosis in transformed and tumorcells, but does not appear to kill normal cells although it isexpressed at a significant level in most normal tissues. Thisprotein binds to several members of TNF receptor superfamilyincluding TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3,TNFRSF10D/TRAILR4, and possibly also to TNFRSF11B/OPG. The activityof this protein may be modulated by binding to the decoy receptorsTNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and TNFRSF11B/OPG that cannotinduce apoptosis. The binding of this protein to its receptors hasbeen shown to trigger the activation of MAPK8/JNK, caspase 8, andcaspase 3. Alternatively spliced transcript variants encodingdifferent isoforms have been found for this gene. [provided byRefSeq].
Morales, J.C., et al. Cancer Lett. 297(1):91-100(2010)Wei, W., et al. Mol. Immunol. 47(15):2475-2484(2010)Niu, T.K., et al. FEBS Lett. 584(16):3519-3524(2010)Pal, R., et al. Breast Cancer Res. Treat. (2010) In press :Johnatty, S.E., et al. PLoS Genet. 6 (7), E1001016 (2010) :
If you have any additional inquiries please email technical services at email@example.com.